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Background: Nasal insufflation of CO2 has been shown to exert antinociceptive respectively antihyperalgesic
effects in animal pain models using topical capsaicin with activation of TRPV1-receptor positive nociceptive
neurons. Clinical benefit from CO2 inhalation in patients with craniofacial pain caused by a putative activation of
TRPV1 receptor positive trigeminal neurons has also been reported. These effects are probably mediated via an
activation of TRPV1 receptor - positive neurons in the nasal mucosa with subsequent central inhibitory effects (such
as conditioned pain modulation). In this study, we aimed to examine the effects of intranasal CO2 on a human
model of craniofacial pain elicited by nasal application of capsaicin.
Methods: In a first experiment, 48 healthy volunteers without previous craniofacial pain received intranasal
capsaicin to provoke trigeminal pain elicited by activation of TRVP1 positive nociceptive neurons. Then, CO2 or air
was insufflated alternatingly into the nasal cavity at a flow rate of 1 l/min for 60 sec each. In the subsequent
experiment, all participants were randomized into 2 groups of 24 each and received either continuous nasal
insufflation of CO2 or placebo for 18:40 min after nociceptive stimulation with intranasal capsaicin. In both
experiments, pain was rated on a numerical rating scale every 60 sec.
Results: Contrary to previous animal studies, the effects of CO2 on experimental trigeminal pain were only marginal.
In the first experiment, CO2 reduced pain ratings only minimally by 5.3% compared to air if given alternatingly
with significant results for the main factor GROUP (F1,47 = 4.438; p = 0.041) and the interaction term TIME*GROUP
(F2.6,121.2 = 3.3; p = 0.029) in the repeated-measures ANOVA. However, these effects were abrogated after continuous
insufflation of CO2 or placebo with no significant changes for the main factors or the interaction term.
Conclusions: Although mild modulatory effects of low-flow intranasal CO2 could be seen in this human model of
TRPV-1 mediated activation of nociceptive trigeminal neurons, utility is limited as observed changes in pain ratings
are clinically non-significant.
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While efficacy of high-flow oxygen has been studied in
several placebo-controlled studies on cluster headache
[1,2] and recently in migraine as well [3,4], little is
known on effects of carbon dioxide (CO2) on the cranio-
facial nociceptive system.
Phasic nasal insufflation of CO2 is used to elicit ex-
perimental trigeminal pain in humans [5] to record* Correspondence: t.juergens@uke.de
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in any medium, provided the original work is pnegative mucosal potentials [6] and chemosensory
evoked potentials [7]. However, if given continuously, a
significant habituation i.e. a decrease of CO2-induced
pain can be observed after some minutes [8]. Likewise,
repeated short stimuli of CO2 with high CO2 concentra-
tions (more than 90% v/v) induce a rapid attenuation of
negative mucosal potentials [6]. These results were
translated into therapeutic utility by showing a reduction
of post-dural puncture headache [9] and chronic cluster
headache [10] upon prolonged inhalation of CO2. Pre-
liminary data also show efficacy of nasal CO2 insufflation
in migraine patients [11,12].an Open Access article distributed under the terms of the Creative Commons
g/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction
roperly cited.
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potent vasodilator, the first studies attributed possible
therapeutic effects to the vasodilating properties on cere-
bral vessels. More recently, CO2 has been shown to be
a powerful modulator of activated nociceptive trigeminal
neurons [13]. Tzabazis and co-workers sensitized rat
cheeks with capsaicin and insufflated CO2 or air nasally
[14]. Nocifensive behaviour defined as facial and hind paw
withdrawal to radiant noxious heat was significantly atten-
uated by higher CO2 flow rates of 0.8 l/min but not of 0.4
l/min CO2 or air. Based on additional pharmacological ex-
periments the authors concluded that CO2 exerts its
antinociceptive, respectively antihyperalgesic effects by ac-
tivation of mucosal primary trigeminal afferents through a
decreased mucosal pH within the nasal cavity.
These findings are well in line with the hypothesis that
TRPV1 receptor positive trigeminal C and A delta fibres
(which are activated by application of capsaicin) may
play a relevant role in the pathogenesis of primary head-
aches such as migraine [15] although this concept has
been challenged recently as TRPV1 receptor blockade
was inefficient in in vivo models of migraine [16].
In summary, there are some clinical but also pre-
clinical data that nasal instillation of CO2 could have
some positive effect on acute headache. We therefore
aimed to examine the modulatory efficacy of intranasal
CO2 on experimental TRPV1-mediated trigeminal pain
elicited by intranasal application of capsaicin in healthy
volunteers to answer the following questions:
1. How painful is prolonged intranasal application of CO2
on a numerical rating scale at a flow rate of 1 l/min?
2. Does intranasally applied CO2 lead to relevant
systemic changes of pH and pCO2 in capillary blood
samples?
3. Does intranasal insufflation of CO2 modulate pain
ratings after intranasal application of capsaicin?
Methods
Study design
We conducted a controlled randomized parallel-group
study to investigate the effects of intranasal CO2 on
TRPV1-mediated trigeminal pain in healthy volunteers.
All participants provided written informed consent prior
to inclusion into the study. Our study was approved by
the local Ethics Committee (protocol number PV3814)
and conformed to the Declaration of Helsinki.
Subjects
Healthy volunteers were recruited among medical stu-
dents at the Medical Faculty of Hamburg University (for
epidemiological details see Table 1). Only subjects aged
18 years or above were considered. Exclusion criteria
were: chronic pain in the medical history, acutecraniofacial pain (such as tooth pain) within the last 4
weeks, intake of analgesics or triptans within the last 12
hours, respiratory tract infection within the last 2 weeks,
bronchial asthma, chronic obstructive lung disease, re-
spiratory insufficiency or other severe lung disease, al-
lergy to capsaicin, pregnancy, lactation or participation
in another clinical trial within the last 3 months.
Experimental design
Pilot study on the effects of nasal CO2 insufflation
In a pilot study (Figure 1) designed to quantify possible
side effects and pain evoked by CO2 insufflation in par-
ticular, 20 subjects received intranasal CO2 (1 l/min) for
18:40 minutes and rated their pain on a numeric rating
scale (NRS) from 0 (no pain) to 10 (worst imaginable pain)
every 80 seconds. To assess possible systemic changes in
pH and CO2 levels, pH and pCO2 were additionally deter-
mined in 10 patients by a capillary blood gas analyses.
This was taken from the earlobe before nasal installation
of CO2 started and immediately after the last pain rating
while the participants were still exposed to CO2.
Experiment 1: alternating nasal application of CO2 and air
after nociceptive stimulation with intranasal capsaicin
In the main study (Figure 1), 48 healthy volunteers received
intranasal CO2 (1 l/min) and air (1 l/min) alternatingly. If
volunteers had already participated in the pilot study, both
experimental sessions were separated by at least 6 weeks.
Again, subjects rated the magnitude of pain verbally on a
numerical rating scale (NRS) ranging from 0 (non-painful)
to 10 (worst imaginable pain).
Initially, participants received one puff of capsaicin spray
(200 μg per puff, custom formulation supplied by the local
pharmacy, for details see below) into the left nostril to
trigger TRPV1-mediated trigeminal nociception. After
three initial pain ratings on a NRS every 60 seconds
(Figure 1), CO2 and air were insufflated for 60 sec each in
an alternating fashion via a nasal cannula. During an inter-
val of 20 sec between exposure to either CO2 or air, no
gas was applied and the participant was asked to rate the
resulting pain on a NRS. After 4 cycles, insufflation was
interrupted for 1 min to allow participants to remove ex-
cessive nasal discharge. However, subjects were asked not
to blow their noses to avoid early removal of the intranasal
capsaicin. Thereafter, 4 identical cycles of CO2, respect-
ively air were given and subjects were asked to rate the
pain on the NRS.
Experiment 2: nasal application of CO2 or placebo after
stimulation with intranasal capsaicin
In the subsequent second experiment separated from
the first experiment by at least 4 weeks all participants
from the first experiment were randomly allocated to
Table 1 Reporting of epidemiological details for the entire cohort and the corresponding subgroups
All CO2 Air Statistics
Mean age (SEM) 24.8 years (±0.5)
24.5 (±0.6) 25.1 years (±0.7) t(46) = -0.636; p = 0.528
Gender ratio (male:female) 24:24
12:12 12:12 χ2(1, n = 48) = 0.000; p = 1.000
Results of unpaired t-tests are considered significant with p < 0.05.
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of 24 subjects each.
Again, participants received 1 puff of capsaicin spray
into the left nostril. Pain ratings on a NRS were noted
every 60 sec over the entire duration of this experiment
(Figure 1). After 120 sec, participants received either con-
tinuous nasal insufflation of CO2 for a total of 18:40 min
via a nasal cannula or placebo (nasal cannula alone with-
out any gas insufflation) and rated the pain on the NRS
as in the pilot study.
Insufflation of CO2 and air
Medical grade CO2 (TMG, Krefeld, Germany) was ad-
ministered from compressed gas cylinders with a volume
of 10 l. By using a combined pressure reducing valve
(200 mbar/4.5 mbar) and flowmeter (Gloor, Burgdorf,
Switzerland) a constant flow of 1 l/min was maintained.Insufflation 
0 5-2  
Capsaicin 
Pain rating (NRS) 
Experiment 2 
Insufflation 
0 5 -2  
Capsaicin 
Pain rating (NRS) 
Experiment 1 
CO2 CO2 Air Air
C
Pilot study 
Insufflation (CO2 ) 
0 5-2  
Pain rating (NRS) 
Figure 1 Experimental setup. NRS: numerical rating scale.Medical grade compressed air was obtained from the
hospital gas reticulation system and delivered at a flow
of 1 l/min by a flow meter (Dräger, Lübeck, Germany).
Nasal cannulae (Dahlhausen, Köln, Germany) were used
to apply both gases locally into both nasal cavities.
Breathing technique
As CO2 should only be insufflated nasally and not in-
haled due to safety concerns, all subjects were trained
before the first experiment. CO2 was applied bilaterally
into the anterior nasal cavity, where highest mucosal re-
sponsiveness of evoked potentials to short pulses of CO2
could be found [17], namely at the anterior septum as
compared to more posterior parts. They were instructed
to breathe-in through the mouth und exhale through the
nose. Before each experiment they were reminded to ad-
here to these instructions.time (min) 1510 
time (min) 15 10 
CO2 CO2 Air Air
O2 /Placebo
20 
time (min) 1510 20 
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One puff of a nasal spray containing 200 μg of capsaicin
(prepared from 1.42 ml capsaicin liquid extract in 10 ml
of refined sesame oil) was applied to the left nostril with
the head in a stooped position to avoid contamination of
the pharynx. Participants were allowed to remove exces-
sive nasal discharge by soaking cotton swaps, but were
asked not to blow their noses to avoid early removal of
intranasal capsaicin.
Capillary blood gas analysis
Blood gas analyses were collected in from the earlobe in
capillary tubes after pretreatment with an ointment
containing 5% benzyl nicotinate (supplied by the hospital
pharmacy) for 10 mins. Immediately afterwards samples
were tested with a blood gas analyzer (ABL5, Radiometer
Medical, Brønshøj, Denmark). The manufacturer’s refer-
ence values for capillary blood gas analysis were as follows:
pH 7.35- 7.45; pCO2 males: 35-48, females: 32-45.
Data evaluation and statistics
Descriptive statistics are given as mean values and stand-
ard errors of the mean. Differences on mean values were
either examined by paired t-tests or by means of a re-
peated measures analysis of variance (ANOVA). For ana-
lysis of pain ratings over time in the pilot study, the factor
TIME (pain ratings 1-15) was used, for other comparisons
of pain ratings a two-way repeated measures ANOVA
with the factors TIME (corresponding pain ratings) and
GROUP (CO2 or air). Comparison of categorical data
(gender) was done by means of the chi square test. In all
tests p values <0.05 were considered significant.
Bivariate correlations were calculated by Pearson’s correl-
ation analysis with p < 0.05 regarded as significant. All ana-
lyses were done with SPSS 20 (IBM, Amonk, NY, USA).
Results
Nociceptive properties of intranasal CO2
When CO2 was given exclusively to 20 healthy subjects (10
male, 10 female, mean age 24.4 ± 0.7 years, range 21-35
years), mean pain ratings over time were 0.6 (± 0.06) out of
10 on the NRS. Pain ratings reached their maximum after 1
min of inhalation with 0.8 (±0.21) out of 10 on the NRS
(see Figure 2). A repeated-measures ANOVA for the factor
TIME (pain ratings 1 to 15) yielded a significant effect
(F14,266 = 2.039; p = 0.001). Seven (35%) of the participants
indicated that they had not perceived any pain at all.
If subjects accidentally inhaled CO2 nasally or started
talking during the training phase, they mostly complained
of a highly unpleasant irritation spreading from the nasal
cavity into the nasal sinus and the pharynx which led to
interruption of the training.
Net changes of pCO2 levels (difference between pCO2
after – pCO2 before insufflation) did not correlate withcorresponding pain ratings in the pilot study (Pearson’s
bivariate correlation: p > 0.05).
Modulatory effects of alternating insufflation of CO2 and
air on TRPV1-mediated nociceptive trigeminal activation
For epidemiological details see Table 1. Mean values for
all pain ratings after insufflation of CO2 (3.6 ± 0.3) and air
(3.8 ± 0.3) respectively differed significantly (t(47) = -2.107;
p = 0.041). Likewise, a repeated-measures ANOVA for
the factors TIME (pain ratings for insufflation 1 to 4) and
GROUP (CO2 or air) yielded no significant main effect
for TIME (F1.3,63.3 = 2.039; p = 0.153), but significant results
for both the main factor GROUP (F1,47 = 4.438; p = 0.041)
and the interaction term TIME*GROUP (F2.6,121.2 = 3.3;
p = 0.029). Mean values are given in Figure 3.
Modulatory effects of continuous insufflation of CO2 or air
on TRPV1-mediated nociceptive trigeminal activation
Age and gender distribution did not differ significantly be-
tween the randomly assigned subgroups receiving either
CO2 or air in experiment 2 (for further details see Table 1).
Mean values for each pain rating are given in Figure 4.
A repeated-measures ANOVA with the factors TIME
(pain ratings 1 to 17) and GROUP (CO2 or air) yielded a
significant main effect for TIME (F2.1, 98.4 = 20.119; p < 0.001),
but not for the factor GROUP (F1,46) = 0.089; p = 0.767)
or the interaction term TIME*GROUP (F2.1, 98.4 = 0.624;
p = 0.548).
There was no baseline difference defined as comparison
of the first pain rating between the CO2 and the air group
after administration of capsaicin and before the first insuf-
flation (CO2: 1.0 ± 0.4; air: 1.1 ± 0.3; t(46) = 0.15; p = 0.902).
Side effects of treatment
No subject terminated the study early or complained
about side-effects apart from unpleasantness or mild
pain upon nasal insufflation of CO2. Most notably, no
patient complained about dyspnea or other clinical side
effects. After 20 min of CO2 insufflation, a significant
shift of capillary pH and capillary pCO2 readings could
be found. pH decreased and pCO2 levels increased sig-
nificantly (see Table 2 for further information). However,
these changes were well within the normative range.
Apart from a parasympathetic activation involving lacri-
mation and rhinorrhea, intranasal capsaicin or insuffla-
tion of CO2 induced no relevant side-effects.
Discussion
Contrary to previous animal studies, the effects of intrana-
sally insufflated CO2 on experimental trigeminal pain were
marginal. Application of CO2 alone resulted in mild pain
and a significant but clinically irrelevant change in capil-
lary pCO2 and pH levels. After nociceptive stimulation of
the first trigeminal branch with intranasal capsaicin (as a
Figure 2 Nociceptive properties of nasally insufflated CO2. Pain ratings on a numerical rating scale from 0 to 10 during nasal insufflation of
CO2 with a flow of 1 l/min for 20 min. Error bars are given as standard error of the mean.
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sensitization), alternating application of CO2 reduced pain
ratings only minimally compared to a sham paradigm with
air, but this effect was abrogated during continuous insuf-
flation of CO2.
Intranasal application of capsaicin as a human model of
trigeminal nociceptive activation
Capsaicin (8-Methyl-N-vanillyl-trans-6-nonenamide) in-
creases release of substance P and simultaneously blocksFigure 3 Alternating insufflation of CO2 and air after administration o
during nasal insufflation of CO2 with a flow of 1 l/min or compressed air fo
and pain rating after intranasal application of capsaicin. After 2 cycles of CO
nasal discharge due to intranasal capsaicin application. Time is given in miits reuptake exerting its effects by activation of the
TRPV1 receptor [18]. This leads to an activation of the
trigemino-vascular system with enlargement of the in-
ternal carotid artery [19] if applied intracutaneously into
the skin innervated by the ophthalmic division (V1) of
the trigeminal nerve but not when applied to the skin
innervated by the mandibular (V3) branch or the fore-
arm. The nasal mucosa is innervated by branches of the
ethmoidal (V1) and the maxillary (V2) nerve [20] with
neurons containing predominantly substance P and - tof capsaicin. Pain ratings on a numerical rating scale from 0 to 10
r 60 sec each followed by an interval of 20 sec to change gas supply
2 and air each a break of 60 sec was made to allow subject to remove
nutes. Error bars are given as standard error of the mean.
Figure 4 Continuous insufflation of either CO2 or air after administration of capsaicin. Pain ratings on a numerical rating scale from 0 to
10 before and during nasal insufflation of CO2 (black dots) with a flow of 1 l/min or compressed air (grey boxes) for 19 minutes after intranasal
application of capsaicin. The time is given in minutes. Error bars are given as standard error of the mean.
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with capsaicin applied to the nostril causes long-lasting
discharges of afferent nerve fibres of the ethmoidal nerve
in guinea pigs [22]. In another study also in guinea pigs,
expression of the immediate-early gene c-fos after intrana-
sal capsaicin was highest in the trigeminal complex with
the subnuclei caudalis and interpolaris [23]. Interestingly,
the majority of cells which innervate the dura show a co-
localisation of TRPV1 receptors and CGRP [24,25].
It has been shown in in vitro experiments with slices
of rat trigeminal nucleus caudalis [26] that activation of
TRPV1 receptors on nociceptive trigeminal afferents
causes release of CGRP. CGRP itself does not activate
meningeal afferents but is thought to facilitate nocicep-
tive transmission in the spinal trigeminal nucleus via
presynaptic modulation of other primary afferents rather
than direct effects on second-order neurons in the spinal
trigeminal nucleus [27,28]. A relevant role in migraine
pathophysiology is supported by the observation that
migraine attacks can be aborted by administration of
CGRP receptor antagonists [29,30]. According to
Lambert and colleagues the TRPV1 receptor antagonist
SB-705498 does not suppress activation in the trigeminal
nucleus caudalis in cats following electrical and mechan-
ical stimulation of nociceptive meningeal and facial af-
ferents. However, sensitisation induced by inflammatoryTable 2 Reporting of safety data for 10 patients taking
part in to pilot study and the corresponding statistical
tests (paired t-tests, considered significant with p < 0.05)
Before CO2 insufflation After CO2 Statistics
pH 7.43 (±0.01) 7.41 (±0.01) t(9) = 3.21; p = 0.011
pCO2 35.0 (±1.4) 37.3 (±1.0) t(9) = -3.15; p = 0.012soup was significantly attenuated by SB-705498 [31]. In
contrast, Summ and co-workers challenged a relevant
role of TRPV1 receptors in migraine pathophysiology as
blockade of TRPV1 receptors did neither modulate ex-
perimentally induced cortical spreading depression nor
neurogenic dural vasodilation or nociceptive transmis-
sion in the trigemino-cervical complex in rats [16].
Regardless of whether TRPV1 receptor positive V1
neurons are indeed involved in migraine pathophysi-
ology or not, they have been associated with other cra-
niofacial pain syndromes such as dental pain where an
upregulation of TRPV1 expression in rat trigeminal gan-
glia was observed in a model of lipopolysaccharide-
induced pulpitis [32]. We note that we did not strive for
a specific model such as migraine headache but a robust
model of craniofacial pain including TRPV1 activation
affecting the first trigeminal branch. In our sample, par-
ticipants showed a transient and significant increase in
pain ratings after nasal application of capsaicin which is
in line with other studies showing a subsequent and
temporary regional sensitization [14,33]. Pain ratings
peaked after 8-9 min which is congruent with an animal
study on neuronal activity in the rat nucleus caudalis
[34]. After application of capsaicin to the eye and the
tongue a delayed activity peaking also after 4-6 min was
found. Thus, intranasal application of 200 μg capsaicin
is a potent model for stimulation of TRPV1 positive
nociceptive neurons of the first trigeminal branch.
Characteristics, tolerability and safety of intranasal
insufflation of CO2
CO2 insufflation was rated as mildly painful by 65% of
patients. We found systemic changes in capillary pH and
pCO2 levels but no relevant alterations beyond the
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l/min is safe. Insufficient delivery of CO2 into the nasal
cavity seems unlikely as changes of pCO2 levels after
nasal insufflation did not correlate with pain ratings in
our pilot study.
Our attempts to mimic CO2 induced unpleasantness re-
spectively pain with vaporized ammonia to establish a ro-
bust sham condition were in vain (data not shown).
Ammonia induced a more stabbing and - at higher con-
centrations - unbearable pain in the nasal cavity with vari-
able pain thresholds. The unpleasantness of intranasal
CO2 in our sample implies that true blinding is not feas-
ible at flow rates of 1 l/min and above as most patients
will notice an unpleasant or painful perception. As clinical
effects were negligible in our sample, potential sources of
bias such as a relevant placebo effect are unlikely.
At lower intranasal flow rates of 0.6 l/min, blinding
seemed to be less problematic in prior studies. Casale
et al. [35] reported that 80% of patients with seasonal al-
lergic rhinitis did not notice nasal stinging or burning
during nasal insufflation of CO2 at 0.6 l/min for only 1
minute – similar to the setup used in the therapeutic
studies in migraine patients by Spierings [11,12].
Inhalation of CO2 was less well tolerated raising doubts
about effective blinding in prior studies reporting efficacy
of inhaled CO2.
Modulatory effects of CO2 insufflation on nociceptive
trigeminal activation
The antihyperalgesic efficacy of CO2 in our study was
small and reached statistical significance only when CO2
and placebo were given in an alternating fashion within
the same subject (experiment 1) – as opposed to applica-
tion of either CO2 or air only in experiment 2. It may be
easier for the participants to sense a subtle analgesic or
anti-hyperalgesic efficacy of CO2 if it is given in a con-
trasting fashion with air as placebo.
As shown by Tzabazis and colleagues in a rat model
[14], nasal insufflation of CO2 with flow rates of 0.8 l/min
attenuated nocifensive behaviour after sensitization with
capsaicin unlike lower flow rates of CO2 (0.4 l/min) or air.
In the nasal mucosa CO2 decomposes into protons and
carbonate catalyzed by mucosal carbonic anhydrase and
activates TRPV1- and ASIC- positive neurons by proton
accumulation. Subsequent, central inhibitory effects are
proposed such as a widespread inhibition of afferent tri-
geminal input though inhibitory interneurons, trans-
segmental inhibitory control circuits or conditioned pain
modulation.
Vause and colleagues showed that incubation of cul-
tured trigeminal ganglions with CO2 or capsaicin resulted
in an acidification of culture medium and a consecutive
nociceptive activation with CGRP release [13]. Similarly,
CO2 attenuated CGRP release by pretreatment withcapsaicin if cultured under isohydric conditions which
prevents extracellular but allows intracellular acidification.
Tzabazis and co-workers observed less intense
and only short-lived antinociceptive or antihyperalgesic
effects of CO2 insufflation on non-sensitized skin as
compared to air insufflation [14]. These findings strongly
argue in favour of activity-dependent effects of CO2, so
that efficacy could have been better in patients with
chronic craniofacial pain. Alternatively, CO2 inhalation
with a potentially different locus of action could repre-
sent a more powerful alternative although tolerability
seems to limit feasibility [9,10].
In summary, intranasal insufflation of CO2 exerts
antihyperalgesic effects in animal models but resulted in
only minor clinical effects in our human model of tri-
geminal pain elicited by activation of nociceptive TRPV1
receptors in healthy volunteers. These moderate effects
question the clinical utility of intranasal CO2 in TRPV1-
mediated pain at flow rates of 1 l/min.
Clinical efficacy of CO2
Marcussen and Wolff successfully treated aura symp-
toms in migraine patients termed as “vasoconstrictor
symptoms” by inhalation of 10% CO2 in either air or
oxygen for 5 min [36]. Likewise, Sikh and Agarwal ex-
posed 40 patients with post-dural puncture headache to
5.6% CO2 mixed with oxygen for 10 min daily which
was repeated up to 2 times if the headache was not re-
lieved [9]. After 3 days, 98% of the patients reported re-
lief compared to 58% of the oxygen only control group.
Despite these impressive clinical results on primary and
secondary headaches, patients inhaled much higher con-
centrations of CO2 suggesting a potentially different
mode of action. In addition, translating these clinical re-
sults to our human model is difficult as the role of the
TRPV1 receptor in migraine pathophysiology has been
challenged [16]. Furthermore, some studies yielded
contrasting results. Engel reported that inhalation of
10% CO2 provoked a headache attack or increased
headache intensity in 18 of 40 subjects with mainly
posttraumatic headache and migraine. CO2-induced
headache attacks or aggravation were less intense than
headaches triggered by histamine and adrenaline [37].
Likewise, Hannerz and Jogestrand reported that ipsilat-
eral pain could be elicited in patients with active epi-
sodic cluster headache during inhalation of 6% CO2
for 6 min [38].
At present, a firm conclusion on the clinical efficacy of
CO2 in primary and secondary headaches is difficult des-
pite promising data from animal experiments. Trials on
the efficacy of inhaled CO2 in various headache syn-
dromes are relatively old and yielded ambiguous results.
Evidence for the efficacy of intranasal CO2 in migraine
has been published in preliminary form.
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Only mild modulatory effects of intranasal insufflation of
CO2 at flow rates of 1 l/min could be seen in a human
model of TRPV1 mediated activation of nociceptive tri-
geminal neurons which is in line with previous studies.
While application was safe, clinical utility at low flow rates
was limited in our model as the therapy is uncomfortable
and changes in pain ratings are therapeutically irrelevant.
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